Opendata, web and dolomites


Identification of promoters and enhancers specific for inflammatory bowel disease and its subtypes

Total Cost €


EC-Contrib. €






Project "IPEIBD" data sheet

The following table provides information about the project.


Organization address
address: NORREGADE 10
postcode: 1165

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 212˙194 €
 EC max contribution 212˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2017-11-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 212˙194.00


 Project objective

Inflammatory bowel disease (IBD) comprises two main types of intestinal disorders: Crohn’s disease (CD) and ulcerative colitis (UC). The incidence and prevalence of IBD is highest in Europe and North America (incidence up to 24 per 100,000 person-years). IBD is not well-understood on a molecular level, and is challenging to diagnose correctly. As the disease is chronic, patients typically require life-long treatment, often with very expensive biological drugs, which are not always effective. Thus, there is a need to increase our understanding the disease, and develop better diagnostic methods so that the correct medication can be applied. In this project we will analyze a unique emerging dataset of controlled gut biopsies taken from a large number of both UC, CD and healthy individuals (109 total) subjected to a unique RNA sequencing technology – CAGE – that can identify novel gene isoforms, transcribed enhancers and non-coding RNAs. As shown in our pilot study, such RNA has great potential as diagnostic biomarkers or even drug targets. The most significant RNA predictors for different IBD subgroups will be used as targets to develop diagnostic kits that will be validated, and ultimately applied, in a clinical setting. The host group of professor Sandelin has set up the CAGE technology that will be used for this analysis and the researcher, Dr Vitezic, did her PhD work on the analysis of data from this technology including human tissue samples while in Japan. The project is involving excellent academic and clinical environments and the applicant will spend time in both. This is a unique clinical genomics proposal focusing novel technology and European strengths, targeting a growing medical problem. Thus, it fits perfectly with the goals for the IF and Horizon 2020.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPEIBD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPEIBD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

DEMOS (2019)

Disfluencies and Eye MOvements during Speech: what can they reveal about language production?

Read More